Background: Hypertensive patients with left ventricular hypertrophy (LVH) need a prompter and more intensive pharmacological treatment than subjects without evidence of cardiac involvement. So the detection of LVH plays an important role for decision-making in hypertensives. Objective: To evaluate the impact of different echocardiographic criteria to define LVH in a more precise stratification of absolute cardiovascular risk in hypertensives without target organ damage (TOD) as assessed by routine investigations. Methods: A total of 100 never treated patients with grade 1 and 2 essential hypertension (53 men, 47 women, age 44 ؎ 12 years) referred for the first time to our outpatient clinic were included in the study. They underwent the following procedures: (1) family and personal medical history, (2) clinic blood pressure (BP) measurement, (3) routine blood chemistry and urine analysis, (4) electrocardiogram, (5) echocardiogram. Risk was stratified according to the criteria suggested by the 1999 WHO-ISH guidelines. TOD was initially evaluated by routine procedures only, and subsequently reassessed by using six different echocardiographic criteria to recognise LVH: (a) left ventricular mass index (LVMI)
Introduction
Echocardiographically determined left ventricular mass (LVM) indexed for either body surface area or height is an independent predictor of cardiovascular Results: According to the first classification based on routine investigations, 46% were low risk and 54% were medium risk patients. Significant changes in risk stratification were obtained when LVH was assessed by echocardiography. A percentage of patients, ranging from 9 (f) to 25% (d), were found to having LVH according to different criteria, and consequently moved from low and medium risk strata to high risk stratum. Conclusions: The detection of LVH by echocardiography allowed a much more accurate identification of high risk patients. In particular our results suggest that: (1) cardiovascular risk stratification only based on a simple routine work-up can often underestimate overall risk; (2) a better standardisation in defining LVH is needed, considering that the impact of cardiac hypertrophy on risk stratification is markedly dependent on the echocardiographic criteria used to diagnose it. Journal of Human Hypertension (2001) 15, 619-625 mortality and morbidity in the general population and among hypertensive patients. [1] [2] [3] [4] [5] The impact of LVH on cardiovascular prognosis may explain why echocardiography, more sensitive and specific than electrocardiography, [6] [7] [8] is largely performed in clinical practice during the initial evaluation of hypertensive patients. However, both the Joint National Committee (JNC VI) and the World Health Organization (WHO)/International Society of Hypertension (ISH) guidelines do not recommend echocardiography in the routine work-up of the hypertensive patient. 9, 10 The question whether and when to employ echocardiogram in hypertensives is being widely debated. [11] [12] [13] Furthermore a number of criteria, based on LVM (indexed for body surface mass, height or height 2.7 , gender specific and not) have been proposed and a considerable controversy exists regarding both optimal method for indexing LVM for body size and threshold values for defining LVH. [14] [15] [16] [17] [18] The aim of the present study was to evaluate the impact of detection of cardiac hypertrophy by different echocardiographic criteria in modifying the level of absolute cardiovascular risk as estimated by usual clinical and laboratory evaluation according to WHO/ISH guidelines in a group of untreated grade 1 and 2 essential hypertensive patients without evidence of target organ damage (TOD) as preliminarily assessed by routine investigations.
Methods

Patients and design
One hundred essential grade 1 and 2 hypertensive patients, never treated previously, and consecutively attending the outpatient clinic of our hypertension centre during a period of 3 months between 1 February and 30 April 2000 were included in the study. Most of the patients had been referred to our centre for the first time by their general practitioners for specialistic advice. Eligibility criteria were: (1) recent diagnosis of arterial hypertension (Ͻ2 years) confirmed in two different consecutive visits diastolic blood pressure (DBP) у90 mm Hg or systolic blood pressure (SBP) у140 mm Hg); (2) absence of TOD according to routine investigations; (3) high quality echocardiograms.
Patients with grade 3 hypertension, secondary hypertension, congestive heart failure, previous myocardial infarction and stroke, cardiac valve diseases, history of coronary artery by-pass, diabetes mellitus and major non-cardiovascular diseases were excluded.
After informed consent during the initial visit, all patients were subjected to the following procedures within 1 to 3 weeks from the initial visit: (1) clinic BP measurement, (2) blood and urine sampling for routine blood chemistry and urine examination, (3) standard 12-lead electrocardiogram, (4) echocardiogram.
Blood pressure measurement
BP was measured in the outpatient clinic by a physician with a mercury sphygmomanometer (1st and 5th phases of Koroktoff sounds taken as SBP and DBP, respectively) after 5-10 min rest in the sitting position during the morning (between 9 and 12 am). Three measurements were taken at 1 min intervals, and the average used to define clinic systolic and diastolic BP.
Echocardiography
M-mode, two-dimensional and Doppler echocardiographic examinations were performed with subjects in the partial left decubitus position, using a commercially available instrument (ATL HDI 3000, Bothell, WA, USA) equipped with a 2.25 MHz imaging transducer. End diastolic left ventricular internal diameter (LVIDd), interventricular septum thickness (IVST) and posterior wall thickness (PWT) were calculated from two-dimensionally guided M-mode tracings and measured in five consecutive cardiac cycles according to the Penn Convention. 19 LVM was determined by Devereux's formula LVM = 1.04
.6} divided by the body surface area, height and height 2.7 in order to evaluate LVM index in g/m 2 , g/m and g/m 2.7 respectively. 20 Left ventricular systolic function was assessed by calculation of fractional shortening (LVIDd − LVIDs)/LVIDd. The relative wall thickness ratio (RWT) was obtained using the standardised formula: RWT = (2 × PWT)/LVIDd.
All echocardiographic examinations were performed by two skilled physicians and recorded on cassettes; reading was made by the same two sonographers who had no knowledge of the subjects characteristics.
As previously reported in our laboratory, the intraobserver and interobserver coefficient of variation for LVMI are 7.4% and 8.7%. 
Stratification of patients by absolute level of cardiovascular risk
We defined the level of global cardiovascular risk of each patient according to criteria suggested by the 1999 WHO/ISH guidelines. 10 The estimate of future absolute risk is based on risk factors on age, gender, smoking, total serum cholesterol, family history of premature cardiovascular disease, the presence of diabetes or TOD, and history or clinical evidence of accompanying clinical complications (cardiovascular or renal disease). Detection of the usual cardiovascular risk factors, and diagnosis of cardiovascular or renal disease were accomplished by careful medical history and physical examination and by the routine examinations recommended by the WHO/ISH guidelines.
The detection of TOD was accomplished by two different approaches: (1) on the basis of the routine examinations recommended by guidelines (ie, serum creatinine, urine analysis and an electrocardiogram) and (2) with the addition of echocardiogram.
The routine search for TOD detection was directed to the search of proteinuria, a slight elevation of plasma creatinine concentration (1.2-2.0 mg/dl or 106-177 mol/l) and electrocardiographic signs of LVH. To detect LVH we used two different electrocardiographic criteria: the SokolowLyon voltage (sum of amplitude of S wave in V 1 and R wave in V 5 or V 6 у35 mm) and the gender-specific Cornell voltage (sum of the amplitude of S wave in V 3 and R wave in aVL Ͼ20 mm in women and Ͼ28 mm in men). LVH was diagnosed when at least one of these two criteria was present. 22 As to ultrasound data, LVH was defined using six different criteria when LVMI exceeded: (a) 120 g/m 2 in men and 100 g/m 2 in women; 23 17 Patterns of left ventricular geometry were defined according Ganau et al: 26 (1) LV concentric remodelling, when a normal LVMI was combined with RWT у0.45; (2) concentric LVH when LVH occurred with a RWT у0.45, (3) eccentric LVH when increased LV mass was associated with a RWT Ͻ0.45.
Statistical analysis
Data have been expressed as means Ϯ s.d. or frequency in percent. Differences between two groups were assessed by unpaired Student's t-test; comparison among multiple groups was performed by ANOVA with the Sheffe post hoc test. A two-tailed value of P Ͻ 0.05 was considered statistically significant. Data management and statistical analysis were performed using Microsoft Access 97 (Microsoft Corps) and SPSS software version 8.0 (SPSS Inc).
Results
Study population
Selection of patients began in February 2000 and ended in April of the same year. The screening process, performed during the first visit at our outpatient unit detected 110 untreated grade 1 and 2 hypertensive patients. Of these three were not included for echocardiographic reasons: unavailability of high quality tracings (two patients) and significant mitral regurgitation (one patient). Five other patients excluded had manifestations of TOD according to routine examinations: slight elevation of plasma creatinine concentration (four patients) and/or electrocardiographic signs of LVH (two patients). Of the 100 patients who were included in the study, 52 were men and 48 were women. The mean age was 44 Ϯ 11 years. The mean clinic BP was 143 Ϯ 12/95 Ϯ 6 mm Hg (Table 1) . According to the definition and classification of BP level suggested by WHO/ISH Guidelines 81 patients had grade 1 hypertension and 19 had grade 2. With regard to other risk factors 27 patients had hypercholesterolaemia (serum total cholesterol у6.5 mmol/l), 29% were smokers and 24% were overweight (BMI у28 in men and у27 in women). Table 2 shows the echocardiographic characteristics of patients; mean systolic endocardial function was in the normal range in all subjects with fractional shortening of 36 Ϯ 6%. Figure 1 shows the frequency distribution of patients according to tertile of absolute LV mass, LV mass indexed by body surface area, and height. 2.7 Depending on the method of LV mass indexation and the criteria used, LVH was present in a percentage ranging from 9% to 25% of patients. The lower prevalence of LVH was found using a non-gender-specific partition value indexed by BSA (d) and the higher prevalence was observed by using a gender specific partition value indexed by height 126/105 g/m (P Ͻ 0.05 or 0.01 vs b, c, d; P = NS vs a and e). Eccentric hypertrophy was present in a percentage from 8 to 22% and was the most frequent type of LVH independently of the criteria used, moreover this geometric pattern was the most common abnormality according to four partition values (a, b, e, f). Concentric hypertrophy was found in a range from 1 to 4%. Concentric remodelling, present in a range from 8 to 10%, was the most common abnormal pattern using the cut-off value 125 g/m 2 for both sexes. Finally, a percentage between 67-82% of all hypertensives was free of any LV structural alteration (Figure 2 ).
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Prevalence of LVH and LV geometric patterns according to different criteria
Impact of echocardiography on cardiovascular stratification
The distinction of patients in the different risk categories on the basis of routine work-up was as follows: 46% of patients were classified as in the low risk and 54% in the medium risk stratum (Figure 3) . Accordingly the detection of LVH by different echocardiographic partition values a proportion of 9 to 25% of patients moved from low and medium risk strata to high risk stratum. The shifts to high risk class tended to be significantly (P Ͻ 0.05) greater among medium risk patient than low risk ones when LVH was diagnosed by criteria a. This tendency was less evident with the other five criteria. Considering the prevalence of LVH as average of six echocardiographic criteria, 7.5% and 10.5% (P = 0.06) patients at low and medium risk respectively were reclassified at higher risk.
Discussion
The goal of antihypertensive treatment is to reduce overall cardiovascular disease risk and thus its mortality and morbidity rates. Recent consensus committees, including JNC VI and WHO/ISH, emphasise the importance of absolute, as opposed to relative, risk in clinical decision-making in patients with hypertension. 9, 10 The recommended approach for initiation of treatment now is based not only on an individual average BP level, but also on the presence or absence of TOD, other risk factors or cardiovascular and renal disease. In this perspective the findings of the present study show that global cardiovascular stratification in a population of predominantly mild hypertensive patients is significantly influenced by the sensitivity of the diagnostic methods used for the detection of TOD and in particular by the kind of diagnostic approach used in detection of LVH. Indeed, when the identification of cardiac damage was performed by echocardiography, the patient distribution in the different risk categories changed substantially if compared with results obtained with a more limited work-up. In the initial stratification, all patients, accordingly to inclusion criteria, were classified in low and medium risk strata, whereas in the stratification based on a more accurate identification of LVH the overall percentage in these two
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Shifts from one to another risk class tended to be greater among patients that the routine approach classified in the medium risk stratum when LVH was defined using the most sensitive diagnostic criteria indexed by BSA (a), but resulted substantially similar among low and medium risk patients when the other cut-off were considered.
Echocardiography in hypertensive patients: when and how?
The WHO/ISH Guidelines 10 recommend that 'echocardiography should be performed whenever the clinical measurement reveals the presence of TOD or suggest the possibility of LVH or of other cardiac
Journal of Human Hypertension disease since increased LV mass is associated with increased cardiovascular risk and this information should be helpful in deciding whether to institute drug treatment'. 10 Our study, besides showing the importance of cardiac ultrasonography in detecting LVH in hypertensives and in more precisely profiling their global risk, also underlines that this approach may be profitably followed in apparently uncomplicated patients with recent diagnosis of grade 1 and 2 essential hypertensives. Under this profile our findings suggest that echocardiography might be particularly useful in patients classified at low and medium risk by routine investigations, as a considerable proportion of them may be reclassified at higher risk after an echocardiographic examination, thus requiring a prompter and more intensive pharmacological treatment, as recommended by guidelines.
In fact, as recently documented by our group, the requirement for cardiac or vascular ultrasonography for decision-making appears less stringent in patients already classified at high risk by routine examination, as the pharmacological approach is, in any case, recommended. 27 A second important point raised by the present study concerns the question: how to define echocardiographic LVH?
LVH on echocardiography is generally found in 20 to 60% of relatively unselected subjects with mild to moderate hypertension 24, 25, 28 and its prevalence varies consistently according to selected thresholds value, as clearly documented in our study. To date, only few surveys have assessed the impact of different echocardiographic diagnostic criteria on the prevalence of LVH in a representative populationbased sample of essential hypertensives. Coca et al 29 investigated 946 hypertensive patients seen in primary care centres, using three cut off values, and found that LVH mass was present in 58% to 72% of subjects.
Wachtell et al 18 studied 941 patients with stage I to III hypertension and LVH by ECG enrolled in the LIFE Study. The prevalence of LVH, according to eight different partition values, ranged from 42% to 77%. 18 The wide variations in LVH prevalence observed in these and other studies 17, 30 stress the need of definite operative criteria in order to allow a more standardised stratification of cardiovascular risk in hypertensives.
The application of particularly conservative diagnostic criteria for defining LVH instead of less restrictive ones can systematically underestimate overall risk in a significant proportion of patients considering that: (1) a linear, independent and powerful relation exists between LV mass and cardiovascular risk in initially untreated essential hypertensives; (2) LVH is independently associated with risk for cardiovascular complications regardless of the use of height-based indexes, genderspecific or gender-independent indexes adjusted for body surface area. 31 
Study strengths and limitations
Our study showed that the impact of echocardiographic detection of LVH in modifying the absolute cardiovascular risk of predominantly mild essential hypertensives may be clinically relevant and its effect is markedly dependent on threshold values used to define LVH. The transfer of our findings into medical practice may have some problems, however. A first brief comment regards the fact that our evaluation of TOD excluded funduscopic examination, which is recommended by WHO/ISH Guidelines. 10 Indeed, our patients underwent non-midriatic retinography 32 with blind lecture of photographers, but an extremely high prevalence (84%) of retinal changes (narrowings or initial arterio-venous crossings) was found. If considered as a marker of TOD, these retinal alterations would have classified almost all patients in the high risk category. Therefore these data suggest that fundoscopic examination should be considered inadequate approach for effective risk stratification in early phases of mild and moderate hypertension. Second, the number of patients included in the present study may not be sufficiently large and, originating from a single centre, may not be fully representative of the general population of uncomplicated hypertensive patients. Third, the experience with quantitative echocardiography may be quite different in usual clinical practice and in a specialised laboratory. Finally, precise quantitative evaluation of cardiac structure cannot be obtained in a significant proportion of patients, especially the elderly or obese, with so-called 'poor echogenic window'.
